Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7452W HIGH $6.12
Volume
147.70 K
Value Traded
465.93 K
Short % Float
3.44%
-5.08%Week
-15.28%1 Month
-20.86%3 Month
-62.44%6 Month
-99.13%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.74 M
EPS (TTM)
-2.45
P/E Ratio
-
Ent. Value
11.96 M
Total Shares
16.54 M
Float Shares
10.20 M
Insiders
39.64%
Institutions
6.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TPST Catalyst Timeline
Dated clinical, regulatory and corporate events for Tempest Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tempest Therapeutics, Inc.
595Total events
25Upcoming
117Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Nancy Freda-Smith appointed to Tempest board of directors and as Audit Committee Chair
▲Partnership / LicenseCorporate
Tempest enters exclusive option agreement with Senlang for CD7-targeted lentiviral in vivo CAR-T platform
▲Safety Data UpdateClinical Data
No Grade 3+ CRS or ICANS observed at highest evaluable dose in Phase 1 BCMA/GPRC5D in vivo CAR-T study
relapsed/refractory multiple myelomasource ↗
▲Partnership / LicenseCorporate
Executed development collaboration with Senlang Biotechnology for in vivo CAR-T candidates
▲Partnership / LicenseTPST-4003Corporate
Development collaboration with Senlang Biotechnology for TPST-4003
autoimmune diseases (myasthenia gravis, multiple sclerosis)source ↗
▲Interim AnalysisTPST-2003Trial
Positive interim data from REDEEM-1 Phase 1/2a trial of TPST-2003 in rrMM
relapsed/refractory multiple myelomasource ↗
▲Manufacturing MilestoneTPST-2003CMC / Inspection
Selection of Cincinnati Children's AGCTC as lead manufacturing partner for TPST-2003
relapsed/refractory multiple myelomasource ↗
●Management ChangeCorporate
Appointment of Andrew Fang, Ph.D., as Head of Business Development
◆Poster PresentationTPST-2003Presentation
Poster reception of REDEEM-1 data at ISCT 2026
relapsed/refractory multiple myelomasource ↗
◆Oral PresentationTPST-2003Presentation
Oral presentation of REDEEM-1 data at ISCT 2026
relapsed/refractory multiple myelomasource ↗
▲Manufacturing MilestoneTPST-2003CMC / Inspection
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's AGCTC
relapsed/refractory multiple myelomasource ↗
▲Topline ReadoutTPST-2003Clinical Data
Positive interim data from REDEEM-1 trial: 100% complete response in all six efficacy evaluable patients
relapsed/refractory multiple myelomasource ↗
◆Management ChangeCorporate
Appointment of Andrew Fang, Ph.D., as Head of Business Development
▲IND ClearanceTPST-1120IND
Clearance to proceed with pivotal trial of amezalpat in China
hepatocellular carcinomasource ↗
▲FDA Feedback ReceivedTPST-1120FDA Meeting
Alignment with FDA on amezalpat Phase 3 study design
hepatocellular carcinomasource ↗
▲EU MAA SubmissionTPST-1120Ex-US Regulatory
Alignment with EMA on amezalpat Phase 3 study design
hepatocellular carcinomasource ↗
◆Trial InitiationTPST-2003Trial
Phase 2b (U.S. registrational) enrollment start
relapsed/refractory multiple myelomasource ↗
◆IND SubmissionTPST-3003IND
File IND (U.S.) for TPST-3003
relapsed/refractory multiple myelomasource ↗
◆First Patient DosedTPST-1495Trial
First patient enrollment expected in Phase 2 study of TPST-1495 in FAP
FAP (familial adenomatous polyposis)source ↗
▲AcquiredCorporate
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc.
▲Interim AnalysisTPST-2003Trial
Positive interim data from REDEEM-1 Phase 1/2a trial of TPST-2003 in rrMM
relapsed/refractory multiple myelomasource ↗
▲IND ClearanceTPST-1120IND
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line HCC in China
first-line hepatocellular carcinomasource ↗
▲Orphan Drug DesignationTPST-1120Designation
Granted orphan drug designation from EMA for amezalpat for HCC
hepatocellular carcinomasource ↗
▲Fast Track DesignationTPST-1120Designation
Granted Fast Track designation by FDA for amezalpat for HCC
hepatocellular carcinomasource ↗
▲Orphan Drug DesignationTPST-1495Designation
Granted Orphan Drug designation by FDA for TPST-1495 for FAP
Familial Adenomatous Polyposissource ↗
▲IND ClearanceTPST-1495IND
Received 'Study May Proceed' letter from FDA for Phase 2 trial of TPST-1495 in FAP
Familial Adenomatous Polyposissource ↗
▼Equity OfferingCorporate
Private placement of common stock and warrants for up to $6 million
▲Partnership / LicenseTPST-2003Corporate
Selection of Cincinnati Children's AGCTC as manufacturing partner for TPST-2003
relapsed/refractory multiple myelomasource ↗
▲Topline ReadoutTPST-2003Clinical Data
Interim results from REDEEM-1 trial of TPST-2003
relapsed/refractory multiple myelomasource ↗
◆AcquisitionCorporate
Tempest closes acquisition of dual-targeting CAR-T assets from Factor Bioscience
▲AcquiredCorporate
Closing of strategic asset acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. and Erigen LLC
▲Topline ReadoutTPST-2003Clinical Data
Positive interim data from REDEEM-1 trial (100% CR in 6 evaluable patients)
relapsed/refractory multiple myelomasource ↗
▲Interim AnalysisTPST-2003Trial
Positive interim data from REDEEM-1 announced earlier in 2026
relapsed/refractory multiple myelomasource ↗
◆Trial InitiationTPST-2003Trial
Phase 2b (China) enrollment start
relapsed/refractory multiple myelomasource ↗
▲Partnership / LicenseTPST-2003Corporate
Acquisition of TPST-2003, a CD19/BCMA dual-CAR T program for EMD
extramedullary disease (EMD)source ↗
▼Equity OfferingCorporate
Closing of up to $8.35 million registered direct offering and concurrent private placement of warrants
▼Equity OfferingCorporate
Up to $8.35 million registered direct offering and concurrent private placement of warrants
◆AcquisitionCorporate
Tempest enters definitive agreements to acquire dual-CAR T programs from Factor Bioscience
Past FDA Catalysts and PDUFA Decisions
How TPST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | TPST-1495 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 84%
Micro Cap(rank 553 of 658)
Percentile Rank
Tempest Therapeutics, Inc. faces pipeline headwinds (25/100), with $179M risk-adjusted pipeline value, led by TPST-1495 twice daily in Solid Tumor (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TPST-1495 twice daily Small moleculeCompletedNCT04344795 | Solid Tumor | Phase 1 | COMPLETED | 89 | Sep 25, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every TPST program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BCMA/GPRC5D dual-targeting in vivo CAR-T candidate | relapsed/refractory multiple myeloma | Phase 1 | 2026-09-15 | in vivo CAR-T generation and expansion at the current highest evaluable dose; no Grade 3 or higher cytokine release syndrome; no immune effector cell-associated neurotoxicity syndromeRead More | Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T PlatformRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Trojanowski JustinOfficer (Corporate Controller) | Grant/Award | 22,000 22,000 held | $0.00 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TPST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 944.00 K | 138.96 K |
TPST Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TPST ranks across every disease it competes in
Competitive Position is a premium feature
See how TPST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTPST News
TPST▼ -7.8%on this news
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Tempest Therapeutics has appointed Nancy Freda-Smith to its board of directors, where she will also serve as Chair of the Audit Committee. With over 30 years of experience in finance and corporate governance, her expertise is expected to add significant value to Tempest. Freda-Smith's background includes leadership roles in Fortune 500 companies and a focus on financial oversight and risk management.
Read more →TPST▲ +60.2%on this news
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Tempest Therapeutics has entered into an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform. This platform complements Tempest's existing CAR-T delivery systems and aims to enhance treatment options for hematologic malignancies and autoimmune diseases. Early clinical data from their lead candidate in multiple myeloma show promising results with a favorable safety profile.
Read more →TPSTTempest Therapeutics Announces Up to $7.5 Million Private Placement
Tempest Therapeutics has announced a private placement to raise up to $7.5 million, consisting of $2.5 million upfront and potential additional proceeds from warrants. The offering includes the sale of shares and warrants at a price of $0.805 per share. The company plans to use the proceeds for working capital and general corporate purposes, with the closing expected around September 14, 2026.
Read more →TPSTTempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Tempest Therapeutics, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. CEO Matt Angel will discuss the company's innovative in vivo CAR-T therapies, including their lead candidate TPST-4003. The presentation will be available via webcast on Tempest's website.
Read more →TPST▼ -13.2%on this news
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest has reported its financial results for Q2 2026 and announced a collaboration with Senlang Biotechnology. This partnership aims to advance the development of TPST-4003, a next-generation CAR-T therapy targeting CD7. The first patient is expected to be dosed in the fourth quarter of 2026, with initial clinical data anticipated shortly thereafter.
Read more →TPSTTempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest Therapeutics has announced a collaboration with Senlang Biotechnology to develop TPST-4003, a next-generation in vivo CAR-T therapy targeting CD7. The partnership aims to initiate a first-in-human trial in patients with neurological autoimmune diseases, including myasthenia gravis and multiple sclerosis, with dosing expected in late 2026. This collaboration is seen as a significant step towards advancing innovative CAR-T therapies.
Read more →TPST▲ +9.1%on this news
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics has announced its next-generation in vivo CAR-T pipeline, focusing on the lead candidate TPST-4003. This candidate combines a CD7-targeted mRNA delivery system with a dual-targeting CAR architecture aimed at treating autoimmune diseases like myasthenia gravis and multiple sclerosis. The first clinical trial is set to begin in Q4 2026, with initial data expected in 2027.
Read more →TPSTTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Tempest Therapeutics has appointed Drake Richey and John Yee, MD, MPH, to its Board of Directors as of June 4, 2026. Both appointees bring extensive experience in their respective fields, with Richey specializing in corporate finance and Yee in medical affairs. The company's President and CEO, Dr. Matt Angel, expressed optimism about how their expertise could contribute to Tempest's goal of providing innovative cancer treatment options. This move aligns with the company's focus on growth and strategic capital allocation in the therapeutic landscape.
Read more →TPST▼ -11.6%on this news· ran to -27% by day 3
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
Tempest Therapeutics has announced the immediate exercise of outstanding warrants, generating approximately $2 million in gross proceeds. The company will issue new short-term warrants that could yield an additional $4 million if fully exercised. The transaction is subject to customary closing conditions and aims to support working capital and corporate purposes.
Read more →TPST▲ +13.6%on this news
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics reported positive interim results from the REDEEM-1 Phase 1/2a trial of TPST-2003 for relapsed/refractory multiple myeloma, achieving a complete response rate of 100% among evaluable patients. The company appointed Andrew Fang, Ph.D., as the new Head of Business Development and announced Cincinnati Children's AGCTC as their lead manufacturing partner. Despite advancements, Tempest reported a significant increase in net losses and a decline in cash reserves compared to the previous year. The company is planning a registrational study for TPST-2003 and seeking strategic partnerships.
Read more →TPST▼ -6%on this news
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
Tempest Therapeutics presented promising clinical data for TPST-2003 at the ISCT 2026 Annual Meeting. The therapy achieved a 100% complete response rate among CAR-T-naïve patients in two Phase 1 trials, demonstrating a favorable safety profile. The results suggest that TPST-2003 could be a leading treatment option for relapsed/refractory multiple myeloma, especially in patients with extramedullary disease.
Read more →TPSTTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Therapeutics will present new clinical data for its dual-targeting CAR-T therapy, TPST-2003, at the ISCT Annual Meeting in May 2026. The latest results from the REDEEM-1 Phase 1/2a trial show a 100% complete response rate among evaluable patients. The therapy aims to enhance treatment outcomes for patients with relapsed/refractory multiple myeloma, particularly those with extramedullary disease.
Read more →TPSTTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Tempest Therapeutics has reached a significant milestone in the development of TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma. The delivery of the lentiviral vector to Cincinnati Children's AGCTC enables the initiation of pivotal studies planned for late 2026. Interim data from the REDEEM-1 trial shows a 100% complete response rate among efficacy evaluable patients, highlighting the therapy's potential.
Read more →TPST▲ +5.1%on this news
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as Head of Business Development to enhance its strategic partnerships and global licensing efforts. Dr. Fang will focus on expanding outreach in China and advancing discussions for the Phase 3-ready amezalpat program. This appointment reflects Tempest's commitment to business development as a core strategic priority.
Read more →TPST▼ -12.1%on this news
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Tempest Therapeutics reported its financial results for 2025, highlighting a strategic acquisition of CAR-T assets and positive interim data from the REDEEM-1 trial of TPST-2003 for relapsed/refractory multiple myeloma. The company aims to initiate a U.S. registrational study for TPST-2003 later this year. Despite a decrease in cash reserves and an increase in net loss, the company remains optimistic about its pipeline and future milestones.
Read more →TPST▼ -19.7%on this news
Tempest Therapeutics Announces Up To $6 Million Private Placement
Tempest Therapeutics has announced a private placement to raise up to $6 million through the sale of shares and warrants. The offering, which is expected to close on March 23, 2026, will provide funds for working capital and corporate purposes. However, the company faces uncertainties regarding the exercise of warrants and market conditions.
Read more →TPSTTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Tempest Therapeutics announced a partnership with Cincinnati Children's Applied Gene and Cell Therapy Center for the development of TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy aimed at treating relapsed/refractory multiple myeloma. The partnership includes tech transfer and IND-enabling manufacturing, with activities expected to complete by Q3 2026. TPST-2003 has shown promising results in the ongoing REDEEM-1 trial, achieving a complete response in all six efficacy evaluable patients as of January 31, 2026. This positioning may present TPST-2003 as a potential leading therapy in its field, subject to FDA approval.
Read more →TPST▼ -6.4%on this news
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Tempest Therapeutics announced promising interim results from the REDEEM-1 trial of TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma. All evaluable patients achieved a complete response, and the therapy demonstrated a favorable safety profile. Tempest plans to present further results and initiate a U.S. registrational study in 2026.
Read more →TPSTTempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
Tempest Therapeutics has outlined its strategic plan to advance its newly acquired dual-targeting CAR-T assets, focusing on the TPST-2003 program. The company aims to maintain a capital-efficient operation while exploring next-generation CAR-T modalities. CEO Dr. Matt Angel emphasized leveraging partner-funded development to generate valuable clinical data without significant internal capital commitment.
Read more →TPSTAccelerating the Development of Advanced Therapies for Cancer Patients February 2026 Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Se
Tempest Therapeutics, Inc. has provided an update on its progress in developing advanced cancer therapies. The company is actively working on an expanded oncology pipeline that includes several initiatives currently in clinical trials. Notably, TPST-2003, a dual-target CAR-T cell therapy, has demonstrated promising results in initial studies, prompting plans for a BLA submission in China by 2027. However, the company cautions that forward-looking statements reflect uncertainties that may affect its future performance and product development.
Read more →About Tempest Therapeutics, Inc.
Headquarters2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
BIOPHARMAWATCH ELITE PLUS
Trade the next TPST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime